Allo-APZ2-OTS clinical trials
Allo-APZ2-OTS is named as an intervention in 2 current clinical trials in our UK, France, Spain, Italy, Poland, Austria, Portugal, Taiwan and USA registers. None are recruiting at the moment. All registered phases are Phase 3. The lead sponsor is RHEACELL GmbH & Co. KG. The most-studied condition is Epidermolysis Bullosa.
Patient leaflets for Allo-APZ2-OTS
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Allo-APZ2-OTS
2 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III, Cross-over)
NCT05464381 · Epidermolysis Bullosa
|
Phase 3 | Active, closed | RHEACELL GmbH & Co. KG | UK, France, Spain, Italy, Poland, Austria, Portugal, Taiwan |
|
Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III)
NCT05838092 · Epidermolysis Bullosa
|
Phase 3 | Active, closed | RHEACELL GmbH & Co. KG | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Allo-APZ2-OTS
1 conditionSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| RHEACELL GmbH & Co. KG | 2 |
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Allo-APZ2-OTS trials
How many clinical trials are testing Allo-APZ2-OTS?
2 current trials in our UK, France, Spain, Italy, Poland, Austria, Portugal, Taiwan and USA registers name Allo-APZ2-OTS as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Allo-APZ2-OTS trials recruiting patients?
Not at the moment. None of the 2 trials in our registers is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
Who sponsors Allo-APZ2-OTS clinical trials?
The lead sponsor is RHEACELL GmbH & Co. KG. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Allo-APZ2-OTS works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Allo-APZ2-OTS works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Allo-APZ2-OTS (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.